Morgan Stanley Assumes Ascendis Pharma at Overweight, Announces Price Target of $250

Benzinga · 07/03 17:23
Morgan Stanley analyst Maxwell Skor assumes Ascendis Pharma (NASDAQ:ASND) with a Overweight rating and announces Price Target of $250.